AML-256 A Phase 1 Study of Gilteritinib in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia: Final Study Results

Pratz, K. W., Cherry, M., Podoltsev, N. A., Altman, J. K., Perl, A. E., Cooper, B. W., Jurcic, J. G., Lin, T. L., Schiller, G. J., Wu, R., Hill, J. E., Gill, S. C., James, A., Rich, E. S., Hasabou, N., & Levis, M. J. (2022). AML-256 A Phase 1 Study of Gilteritinib in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia: Final Study Results. Clinical Lymphoma Myeloma and Leukemia, 22, S230. https://doi.org/10.1016/s2152-2650(22)01255-1
Authors:
Keith W. Pratz
Mohamad Cherry
Nikolai A. Podoltsev
Jessica K. Altman
Alexander E. Perl
Brenda W. Cooper
Joseph G. Jurcic
Tara L. Lin
Gary J. Schiller
Ruishan Wu
Jason E. Hill
Stanley C. Gill
Angela James
Elizabeth Shima Rich
Nahla Hasabou
Mark J. Levis
Affiliated Authors:
Joseph G. Jurcic
Columbia Affiliation:
Author Keywords:
acute myeloid leukemia
adverse events
aml
clinical response
flt3, gilteritinib
phase i
elink
Publication Type:
Article
Unique ID:
10.1016/S2152-2650(22)01255-1
DOI:
10.1016/S2152-2650(22)01255-1
Journal:
Clinical Lymphoma, Myeloma and Leukemia
Publication Date:
Data Source:
Scopus
Source Link:
View Scopus Record

Record Created: